a和Ⅰb)吡咯并嘧啶類化合物,經(jīng)體外細(xì)胞試驗(yàn)測定其對JAK3激酶的抑制活性。結(jié)果 設(shè)計并合成了8個新化合物,結(jié)構(gòu)經(jīng)1H-NMR和HR-MS確證。初步活性測試結(jié)果顯示Ⅰa-1和Ⅰb-3對JAK3的抑制強(qiáng)度與陽性對照藥tofacitinib相近。結(jié)論 目標(biāo)化合物對JAK3依賴的DAUDI細(xì)胞抑制活性較好,對非JAK3依賴的BT-20細(xì)胞抑制作用弱。;Objective To design and synthesize pyrrolopyrimidines and study their JAK3 inhibitory activities. Methods The two kinds of pyrrolopyrimidines (Ia and Ib)were synthesized from 4-chloro-7H-pyrrolo[2,3-d]pyrimidine via substitution reaction, amino deprotection, and N-acetylation reaction. Their JAK3 inhibitory activities were tested by in vitro cell assay. Results Eight novel compounds were synthesized and their structures were confirmed by 1H-NMR and HR-MS. The in vitro activity experiments showed that compounds Ia-1 and Ib-3 had good inhibition against JAK3, and it was near to control drug tofacitinib. Conclusion Target compounds had good inhibition on JAK3-depended DAUDI cells, and rarely inhibition on non-JAK3-depended BT-20 cells."/>